TScan Therapeutics Statistics
Total Valuation
TCRX has a market cap or net worth of $62.99 million. The enterprise value is -$25.84 million.
Important Dates
The last earnings date was Wednesday, November 12, 2025, before market open.
| Earnings Date | Nov 12, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
TCRX has 56.75 million shares outstanding. The number of shares has increased by 6.36% in one year.
| Current Share Class | 52.47M |
| Shares Outstanding | 56.75M |
| Shares Change (YoY) | +6.36% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 0.76% |
| Owned by Institutions (%) | 47.88% |
| Float | 44.03M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 7.48 |
| Forward PS | 8.01 |
| PB Ratio | 0.44 |
| P/TBV Ratio | 0.44 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.44, with a Debt / Equity ratio of 0.66.
| Current Ratio | 6.44 |
| Quick Ratio | 6.32 |
| Debt / Equity | 0.66 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -52.15 |
Financial Efficiency
Return on equity (ROE) is -76.44% and return on invested capital (ROIC) is -33.24%.
| Return on Equity (ROE) | -76.44% |
| Return on Assets (ROA) | -30.45% |
| Return on Invested Capital (ROIC) | -33.24% |
| Return on Capital Employed (ROCE) | -63.80% |
| Revenue Per Employee | $43,195 |
| Profits Per Employee | -$731,272 |
| Employee Count | 195 |
| Asset Turnover | 0.03 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -75.44% in the last 52 weeks. The beta is 1.00, so TCRX's price volatility has been similar to the market average.
| Beta (5Y) | 1.00 |
| 52-Week Price Change | -75.44% |
| 50-Day Moving Average | 1.71 |
| 200-Day Moving Average | 1.67 |
| Relative Strength Index (RSI) | 38.57 |
| Average Volume (20 Days) | 1,109,888 |
Short Selling Information
The latest short interest is 1.74 million, so 3.07% of the outstanding shares have been sold short.
| Short Interest | 1.74M |
| Short Previous Month | 1.68M |
| Short % of Shares Out | 3.07% |
| Short % of Float | 3.96% |
| Short Ratio (days to cover) | 2.33 |
Income Statement
In the last 12 months, TCRX had revenue of $8.42 million and -$142.60 million in losses. Loss per share was -$2.51.
| Revenue | 8.42M |
| Gross Profit | -12.54M |
| Operating Income | -148.67M |
| Pretax Income | -142.60M |
| Net Income | -142.60M |
| EBITDA | -145.81M |
| EBIT | -148.67M |
| Loss Per Share | -$2.51 |
Full Income StatementBalance Sheet
The company has $184.45 million in cash and $95.62 million in debt, giving a net cash position of $88.83 million or $1.57 per share.
| Cash & Cash Equivalents | 184.45M |
| Total Debt | 95.62M |
| Net Cash | 88.83M |
| Net Cash Per Share | $1.57 |
| Equity (Book Value) | 144.02M |
| Book Value Per Share | 2.54 |
| Working Capital | 158.96M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$130.73 million and capital expenditures -$5.12 million, giving a free cash flow of -$135.85 million.
| Operating Cash Flow | -130.73M |
| Capital Expenditures | -5.12M |
| Free Cash Flow | -135.85M |
| FCF Per Share | -$2.39 |
Full Cash Flow StatementMargins
| Gross Margin | -148.85% |
| Operating Margin | -1,765.01% |
| Pretax Margin | -1,692.96% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
TCRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -6.36% |
| Shareholder Yield | -6.36% |
| Earnings Yield | -226.38% |
| FCF Yield | -215.67% |
Analyst Forecast
The average price target for TCRX is $8.50, which is 665.77% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $8.50 |
| Price Target Difference | 665.77% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (5Y) | 109.83% |
| EPS Growth Forecast (5Y) | -21.15% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
TCRX has an Altman Z-Score of -2.98 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -2.98 |
| Piotroski F-Score | 1 |
